Australpharma Competitors

Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial. Fusion is headquartered in Hamilton, ON, with offices in Boston, MA.

Medicure Inc (TSXV:MPH) is a pharmaceutical company focused on the development and commercialization of cardiovascular medicines for the U.S. market. Our vision is to become a leading pharmaceutical company within the U.S., offering a growing portfolio of products that improve patients' lives. We take pride in providing safe, efficacious, and cost-effective cardiovascular medicines that benefit both patients and healthcare providers. Currently, we focus on the marketing & distribution of: 1. AGGRASTAT® (tirofiban hydrochloride) injections, a hospital-based product used in the cardiac catheterization lab. AGGRASTAT is the #1 used medication of its class in the U.S. 2. ZYPITAMAG® (pitavastatin) tablets, the latest statin medication approved by the FDA in 2017. In 2020, we acquired Marley Drug, a local pharmacy in North Carolina. Our acquisition of Marley Drug increases patient access to medications, including Medicure's primary care drug, ZYPITAMAG® (Pitavastatin) tablets. At Medicure, our passion drives us to innovate and find solutions to better support patients. For more information, please see our website at www.medicure.com and follow us on Twitter at @MedicureInc. For guidelines on engaging with Medicure on social media, please visit bit.ly/MedicureSocial

Pharmatech, Inc. is a Site Management Organization (SMO) that specializes in creating efficiencies in the clinical trial process. Through an organized network of clinics, the Company focuses on advancing the development of products for a broad range of pharmaceutical and biotechnology companies, and on promoting the inclusion of clinical trials in the spectrum of patient treatment options.